Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease
Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…Prevalence and clinical characteristics of young onset Parkinson’s Disease among Nepalese Population
Objective: To know the prevalence and clinical characteristics of young onset Parkinson’s Disease among Nepalese Population Background: Parkinson’s disease (PD) is a neurodegenerative disease which…Asymptomatic Gaucher disease presented as Parkinsonism in 61 years old patient.
Objective: Gaucher disease is an inherited disease caused by a mutation in the glucocerebrosidase gene, causing visceral, hematologic, and skeletal involvement. [1] [2] We report…Response of extraocular movements in parkinson’s disease to levodopa: an electrooculographic perspective
Objective: To determine the response of latencies and amplitudes of saccadic movements to Levodopa in idiopathic Parkinson’s Disease. Background: Neurodegeneration in Parkinson’s Disease (PD) increases…Feasibility, Reliability and Value of Remote Levodopa Challenge Test in Parkinson’s Disease
Objective: To demonstrate the feasibility, reliability, and value of the remote L-dopa challenge test (LCT) in candidate screening for deep brain stimulation (DBS) in patients…Exercise and levodopa metabolism in Parkinson disease
Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…Clinical and risk profiles of Parkinson’s disease from a large pan-India cohort: interim observations of the GAP-India study
Objective: To create a pan-Indian clinical repository of Parkinson’s Disease (PD). Background: The genetic risk for PD in India is unknown. The Luxembourg-German India Alliance…OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?
Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis
Objective: To report the clinical course of secondary parkinsonism due to methanol toxicity with good levodopa responsiveness in the background of COVID-19 crisis. Background: The…Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial
Objective: This study aimed to assess the efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease (PD) patients with motor fluctuation. Background: Delayed…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 57
- Next Page »